XBP vs QUAD vs XRX vs SRPT vs JPM

For growth investors, XBP Global Holdings, Inc.

(XBP) is the stronger pick with 454. 1% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). XBP Global Holdings, Inc. (XBP) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate Quad/Graphics, Inc. (QUAD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, XBP Global Holdings, Inc.

(XBP) is the cheapest at 0. 0x versus JPMorgan Chase & Co. at 16. 0x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 4. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Quad/Graphics, Inc.

(QUAD) delivered a total return of +119. 3%, compared to -82. 2% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: JPM returned +465. 8% versus XBP's -74. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quad/Graphics, Inc.

(QUAD) is the lower-risk stock at 0. 74β versus Xerox Holdings Corporation's 2. 62β — meaning XRX is approximately 253% more volatile than QUAD relative to the S&P 500. On balance sheet safety, Sarepta Therapeutics, Inc. (SRPT) carries a lower debt/equity ratio of 91% versus 6% for Xerox Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XBP Global Holdings, Inc.

(XBP) is pulling ahead at 454. 1% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: XBP Global Holdings, Inc. grew EPS 230. 0% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, XBP leads at 63. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XBP Global Holdings, Inc.

(XBP) is the more profitable company, earning 139. 5% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 139. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 4. 3x forward P/E versus 14. 4x for JPMorgan Chase & Co. — 10. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XRX: 195. 4% to $10. 25.

In this comparison, XRX (16.

2% yield), QUAD (3. 8% yield), JPM (1. 9% yield) pay a dividend. XBP, SRPT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, SRPT: -21. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (XBP (Technology) and QUAD (Industrials) and XRX (Technology) and SRPT (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: XBP is a small-cap high-growth stock; QUAD is a small-cap deep-value stock; XRX is a small-cap income-oriented stock; SRPT is a small-cap high-growth stock; JPM is a large-cap deep-value stock. QUAD, XRX, JPM pay a dividend while XBP, SRPT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.